Atara Biotherapeutics saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Atara Biotherapeutics‘s patent filings and grants. Buy the databook here.
Atara Biotherapeutics has been focused on protecting inventions in Australia(AU) with one publication in Q2 2024
The Australia(AU) Patent Office dominates the patent grants with nearly 50% of grants. The Australia(AU), and Israel(IL) patent Office are among the top ten patent offices where Atara Biotherapeutics is filings its patents. Among the top granted patent authorities, Atara Biotherapeutics has 50% of its grants in Australia(AU) and 50% in Israel(IL).
Immatics and University of Pennsylvania could be the strongest competitors for Atara Biotherapeutics
Patents related to climate change and immuno-oncology lead Atara Biotherapeutics's portfolio
Atara Biotherapeutics has the highest number of patents in climate change followed by, immuno-oncology and rare diseases. For climate change no patents were filed and 25% of patents were granted in Q2 2024.
Multiple sclerosis related patents lead Atara Biotherapeutics portfolio followed by epstein–barr virus (hhv-4) infections, and polyomavirus infections
Atara Biotherapeutics has highest number of patents in multiple sclerosis followed by epstein–barr virus (hhv-4) infections, polyomavirus infections.
For comprehensive analysis of Atara Biotherapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.